Inclusion Criteria:

          -  Females should agree to use adequate contraceptive measure, should not be breast
             feeding and must have a negative pregnancy test prior to start of dosing if of
             child-bearing potential or must have evidence of non-child-bearing potential by
             fulfilling one of following criteria at screening; Post-menopausal defined as aged
             more than 50 years and ameorrhoeic for at least 12 months following cessation of all
             exogenous hormonal treatments; Documentation of irreversible surgical sterilization by
             hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal
             ligation; Women under 50 years old would be considered postmenopausal if they have
             been ameorrhoeic for at least 12 months following cessation of exogenous hormonal
             treatment, and have serum follicle-stimulating hormone (FSH) and luteinizing hormone
             (LH) levels in postmenopausal range for the institution

          -  Male participants who have not undergone a vasectomy must agree to use barrier
             contraception that is, condoms, and refrain from donating sperm until 3 months after
             last drug is taken

          -  During the study, and for 3 months after receiving the last dose of study drug, female
             participants must agree not to donate eggs (ova, oocytes) and male participants must
             agree not to donate sperm for the purposes of assisted reproduction

          -  In Part D: Participants outside Korea with histologically or cytologically (that is,
             using pleural effusion, ascites) confirmed Non-Small Cell Lung Cancer (NSCLC) with
             previously diagnosed epidermal growth factor receptor single activating mutation
             positive (EGFRm+), and who have had progressive disease on prior epidermal growth
             factor receptor- Tyrosine kinase inhibitor (EGFR-TKI) therapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 with no
             deterioration over the previous 2 weeks and a minimum life expectancy of 3 months

        Exclusion Criteria:

          -  An unapproved investigational product from another clinical study within 30 days of
             the first dose of study treatment

          -  Treatment with an EGFR TKIs (example: erlotinib or gefitinib) within 8 days or
             approximately 5x half-life, whichever is the longer, of the first dose of study
             treatment or other investigational products within approved indication of marketed
             product (if sufficient wash-out time has not occurred due to schedule or PK
             properties, an alternative appropriate wash-out time based on known duration of time
             to reversibility of drug related adverse events could be agreed upon by sponsor and
             the Investigator)

          -  Any cytotoxic chemotherapy or other anticancer drugs for the treatment of advanced
             NSCLC from a previous treatment regimen within 14 days of the first dose of study
             treatment

          -  Symptomatic spinal cord compression (if steroid treatment is not required within at
             least 2 weeks prior to the start of the study treatment then the participant may be
             enrolled)

          -  Brain metastases with symptomatic and/or requiring emergency treatment (example;
             Steroid for at least 2 weeks prior to start of study treatment)